Brukercellularanalysis
1 known investors
Bruker Cellular Analysis develops technologies for live single-cell biology research, combining optofluidics, live single-cell imaging, functional cell biology, and multiomic data to study cellular function and molecular mechanisms. It serves scientists in academia, biotech and pharmaceutical companies, and contract research organizations, supporting work in cell therapy, therapeutic antibody discovery, vaccine development, and cell line development.
Also known as BCA · Berkeley Lights, Inc. · Bruker Cellular · Bruker Cellular Analysis Inc · PhenomeX
Investors · 1
Company profile
researched Aug 2026Bruker Cellular Analysis (BCA) develops instruments, consumables and software for live single-cell biology, combining optofluidics, live single-cell imaging, functional cell biology and multiomic data. Its portfolio is organized into two product suites: a Beacon optofluidic suite (Beacon, Beacon Discovery, Beacon Select, Beacon Quest and Lightning systems, plus a Culture Station) used to functionally profile live single cells for therapeutic antibody discovery, T cell interrogation and cell line development; and a proteomic barcoding suite (IsoLight and IsoSpark systems, with chips such as Meteor) used to capture multiplexed cytokine, chemokine and phosphoprotein signatures from single cells and to run quantitative bulk proteomics. Data analysis is handled through the Cell Analysis Suite (CAS) software, with the 4.1 release the most recent version highlighted by the company.
On the Beacon platform, optoelectronic positioning is combined with microfluidics to move individual cells into Nanopen chambers on OptoSelect chips, where secreted antibodies and cellular responses are measured with time-lapse fluorescent imaging across multiple sequential assays on the same live cells. On-chip mRNA capture supports paired heavy/light chain BCR sequencing (OptoSeq Barcoded BCR) on standard Illumina platforms, with contigs assembled by the company's proprietary PrimeSeq BCR software. A published company campaign screened approximately 35,000 mouse B cells across three chips against VEGFR1, VEGFR2 and VEGFR3, identifying 3,106 antigen-specific pens and sequencing 1,142 selected cells.
Application areas span discovery and basic research (antibody discovery, T cell profiling), bioprocessing (cell line development), translational research (cell therapy development) and single-cell and bulk proteomics characterization, across research areas including cancer, immunology, cell and gene therapy, infectious diseases, inflammation and neurology.
Founding story
Predecessor company Berkeley Lights, Inc. was founded in 2011 and was based in Emeryville, California.
Business model
The company sells laboratory instrument platforms together with associated consumable chips and assay kits, analysis software (Cell Analysis Suite) and technical support, delivered through a customer support portal offering protocols, manuals and software patches. Access to the platforms is also provided indirectly through a network of trained third-party service providers, and distribution in some regions is handled by local life-science technology distributors.
Revenue is derived from sales of instrument systems (Beacon and IsoSpark/IsoLight families), consumables such as OptoSelect and Meteor chips and NGS prep kits, and related software and support. Reported revenue was $78.6M for 2022.
Traction
Instruments are deployed at academic and industry sites worldwide, including a Caltech center dedicated to the Beacon platform, an A*STAR Centre of Excellence in Singapore established in October 2023, the first single-cell optofluidic platform in Southwest China at the Chongqing International Institute for Immunology, and the University of Texas at Arlington as the first U.S. university to acquire the Beacon Discovery instrument. Third-party researchers have published protocols using the Beacon platform, and reported 2022 revenue was $78.6M.
Latest developments
Recent activity includes the introduction of Cell Analysis Suite 4.1 software, promotion of the benchtop Beacon Discovery system following its Scientist Top Innovations Award for 2025, a webinar with Emory University on plasma cell BCR function and repertoires using Beacon Discovery, a February 2026 blog on linking live T cell function with spatial biology, a September seminar on real-time single-cell functional analysis in Oxford, England, and the March 2026 acquisition of a Beacon Discovery instrument by the University of Texas at Arlington.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company is positioned in single-cell analysis and functional proteomics tools, and is compared with Miltenyi Biotec, 10x Genomics, Cytek Biosciences and Akoya Biosciences, as well as Mission Bio, LumaCyte and Illumina. It operates as a subsidiary of Bruker Corp. Its Beacon Discovery system received The Scientist Top Innovations Award for 2025.
Positioning emphasizes function-first, live single-cell workflows: multiple sequential assays performed on the same living cells with temporal readouts and multiple parameters linked to individual cells, followed by recovery of selected cells for sequencing. Customers cite the ability to link multi-parameter data to a single cell and precise control over cell movement for flexible assay design, and the Beacon Discovery system is presented as a compact benchtop format intended to make the optofluidic platform accessible to a broader range of academic, translational and biotech labs.
Technology
Core technology couples optoelectronic positioning (OEP) with microfluidics to manipulate individual live cells into Nanopen chambers on OptoSelect chips, enabling precise cell sorting, multiple sequential functional assays on the same cells, real-time imaging of cellular interactions and recovery of cells of interest for downstream multiomics. Complementary proteomic barcoding chips measure highly multiplexed secreted and intracellular protein signatures at single-cell and bulk scale. Software components include the Cell Analysis Suite and PrimeSeq BCR for assembling paired full-length heavy and light chain sequences from Illumina reads.
Go-to-market
Direct engagement with research labs is supplemented by product demonstrations, virtual product tours, webinars, seminars, a resource and publication library, and customer spotlight case studies. A global network of recommended service providers trained by the company on the Beacon platform gives prospective users access to the technology without purchasing an instrument, and regional distributors such as Omixys cover Central and Eastern Europe.
Researchers in academia and translational research centers, biotech and pharmaceutical companies, contract research and contract development and manufacturing organizations, and core facilities. Named users and partners include Caltech's Beacon Center for Single Cell Biology, A*STAR in Singapore, the Chongqing International Institute for Immunology, CONCEPT at NIBRT, Edinburgh Genome Foundry, ChemPartner, Curia, Abveris, Mycenax, the Medical College of Wisconsin and the University of Texas at Arlington.
Geography
Company records list a headquarters at 3350 Monte Villa Parkway, Bothell, Washington, and an Emeryville, California address at 5980 Horton St. Customers, service providers and events span the Americas, Europe (including England, Ireland and Poland via distribution), China and the wider Asia-Pacific-Japan region.
History
The business traces to Berkeley Lights, Inc., which was founded in 2011 and traded publicly under the ticker CELL. Berkeley Lights merged with IsoPlexis to form PhenomeX, which was subsequently brought under Bruker Corp. and renamed Bruker Cellular Analysis; company records date the Bruker Cellular Analysis entity to 2023. Since then the group has launched the Beacon Quest optofluidic system and Meteor chips for IsoSpark (both 2023), the benchtop Beacon Discovery system, and version 4.1 of the Cell Analysis Suite software.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 6
launches, deals, and filingsThe University of Texas at Arlington became the first U.S. university to acquire the Beacon Discovery instrument from Bruker Cellular Analysis.
The A*STAR SIgN-BCA Centre of Excellence, a Single Cell Cloning Platform built on the Beacon Optofluidic System, was established to serve as a regional hub for training and research services in antibody discovery, immune cell profiling and cell line development.
Meteor chips were introduced on the IsoSpark platform for high-throughput, quantitative and automated bulk proteomics.
Bruker Cellular Analysis introduced the Beacon Quest, a two-chip optofluidic system featuring Opto T Cell Profiling workflows for immunotherapy translational research, Opto Plasma B Discovery and Opto Memory B Discovery workflows for lead antibody selection, and Opto Cell Line Development workflows for high-throughput cloning.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Brukercellularanalysisbrukercellularanalysis.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Brukercellularanalysis do?
- Bruker Cellular Analysis builds optofluidic and proteomic systems for live single-cell functional and multiomic analysis.
- Who are Brukercellularanalysis's investors?
- Brukercellularanalysis's investors include Atinum Investment Co. Ltd..